Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study to Evaluate th

Indication
Relapsing Multiple Sclerosis

Other upcoming events for TGTX

Phase 3 ReadoutPhase 3 Topline: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIb/III Study to Assess the Effica
Phase 3 ReadoutPhase 3 Topline: Evaluating Safety, Efficacy and Pharmacokinetics of a Modified Regimen of Ublituximab (ENHANCE )
Phase 3 ReadoutPhase 3 Topline: Multicenter, Double-Masked, Randomized, Vehicle-Controlled 12-Month Parallel Comparison of the Safet
Phase 3 ReadoutPhase 3 Topline: An Open Label Extension Study of Ublituximab in Subjects With Relapsing Multiple Sclerosis
Phase 3 ReadoutPhase 3 Topline: Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study to Evaluate th — TGTX Phase 3 Readout | BioSniper